Tobacco Boosts In-Store Advertising

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

WASHINGTON-Tobacco companies, which were banned from touting their products on billboards last year, have increased their advertising at point-of-sale locations, such as convenience stores, according to a new study funded by the Robert Wood Johnson Foundation.

WASHINGTON—Tobacco companies, which were banned from touting their products on billboards last year, have increased their advertising at point-of-sale locations, such as convenience stores, according to a new study funded by the Robert Wood Johnson Foundation.

In-store advertising was present in 80% of the stores visited, an increase of 27% over the display ads present prior to the billboard ban. Exterior advertising was observed at 60% of the stores, an increase of 22%. Tobacco promotions were available at 52% of stores visited after the ban, an increase of 65%.

“The shift in advertising expenditure is likely to mean that any intended effect of the billboard advertising ban—as well as other advertising restrictions—will not be fully realized,” said lead researcher Frank Chaloupka, PhD, of the University of Illinois at Chicago.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content